## Edgar Filing: Hayden Michael R - Form 4

Hayden Michael Form 4	R										
June 05, 2018											
FORM 4	UNITED	STATES	SECU	DITIES /	ND FV	СНАМСЕ		ΛT	PPROVAL		
	UNITED	STATES		shington				Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations	<b>STATEN</b> Filed put	rsuant to S	<b>F CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> Section 16(a) of the Securities Exchange Act of 1934,					Estimated burden ho response	ted average hours per		
may continue. See Instruction 1(b).	1			•	•	npany Act 1y Act of 1	of 1935 or Secti 940	on			
(Print or Type Respo	onses)										
Hayden Michael R Syn			Symbol	2. Issuer Name <b>and</b> Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]			5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (	Middle)		of Earliest T		-	(Cho	eck all applicabl	le)		
C/O XENON PHARMACEU' 3650 GILMORI	FICALS INC	,		Day/Year)	Tansaction		X Director Officer (giv below)		% Owner her (specify		
BURNABY, A1	(Street) V5G 4W8			endment, D onth/Day/Yea	-	l	6. Individual or Applicable Line) _X_ Form filed by Form filed by Person		Person		
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivative	Securities A	cquired, Disposed	of. or Beneficia	ally Owned		
	ansaction Date hth/Day/Year)		ed Date, if	3. Transactio Code	4. Securit nAcquired Disposed (Instr. 3,	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Report of	n a separate line	e for each cla	ass of sec	urities bene	Perso inforr requi	ons who res nation cont red to respo ays a curre	or indirectly. spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible	Beneficially Owner securities)	1			
1. Title of 2.	3. Trans	saction Date	3A. Dee	emed	4.	5. Number	of 6. Date Exerci	sable and	7. Title and Amou		

## Edgar Filing: Hayden Michael R - Form 4

	ecurity 1str. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5)		/Year)	(Instr. 3 and	4)	(
					Code V	(A) (	D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
O (F	tock ption Right to uy)	\$ 6.2	06/04/2018		A	15,000	<u>(1)</u>	06/03/2028	Common Shares	15,000	
Reporting Owners											
	Do	norting Ormon	Nome / Address		Relation	ships					

<b>Reporting Owner Name / Address</b>	Kelauonsinps					
	Director	10% Owner	Officer	Other		
Hayden Michael R C/O XENON PHARMACEUTICALS INC 200 - 3650 GILMORE WAY BURNABY, A1 V5G 4W8	Х					
Signatures						
/s/ Joanne Smartt,	5/2010					

75/ Joanne Smartt,	06/05/2018			
Attorney-in-fact	00/03/2018			

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares
  (1) subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.